JP2017537940A - 増殖性疾患の処置に有用な融合１，３−アゾール誘導体 - Google Patents
増殖性疾患の処置に有用な融合１，３−アゾール誘導体 Download PDFInfo
- Publication number
- JP2017537940A JP2017537940A JP2017531478A JP2017531478A JP2017537940A JP 2017537940 A JP2017537940 A JP 2017537940A JP 2017531478 A JP2017531478 A JP 2017531478A JP 2017531478 A JP2017531478 A JP 2017531478A JP 2017537940 A JP2017537940 A JP 2017537940A
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- unsubstituted
- compound
- formula
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462090290P | 2014-12-10 | 2014-12-10 | |
| US62/090,290 | 2014-12-10 | ||
| PCT/US2015/065044 WO2016094688A1 (en) | 2014-12-10 | 2015-12-10 | Fused 1,3-azole derivatives useful for the treatment of proliferative diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017537940A true JP2017537940A (ja) | 2017-12-21 |
| JP2017537940A5 JP2017537940A5 (enExample) | 2019-02-07 |
Family
ID=55073117
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017531478A Pending JP2017537940A (ja) | 2014-12-10 | 2015-12-10 | 増殖性疾患の処置に有用な融合１，３−アゾール誘導体 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US10017520B2 (enExample) |
| EP (1) | EP3230279A1 (enExample) |
| JP (1) | JP2017537940A (enExample) |
| AU (1) | AU2015360416A1 (enExample) |
| CA (1) | CA2968884A1 (enExample) |
| WO (1) | WO2016094688A1 (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA52119A (fr) | 2015-10-19 | 2018-08-29 | Ncyte Corp | Composés hétérocycliques utilisés comme immunomodulateurs |
| PT3377488T (pt) | 2015-11-19 | 2022-11-21 | Incyte Corp | Compostos heterocíclicos como imunomoduladores |
| SI3394033T1 (sl) | 2015-12-22 | 2021-03-31 | Incyte Corporation | Heterociklične spojine kot imunomodulatorji |
| US10106555B2 (en) | 2016-02-16 | 2018-10-23 | Massachusetts Institute Of Technology | Max binders as MYC modulators and uses thereof |
| WO2017192961A1 (en) | 2016-05-06 | 2017-11-09 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| EP3464279B1 (en) | 2016-05-26 | 2021-11-24 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| PL3472167T3 (pl) | 2016-06-20 | 2022-12-19 | Incyte Corporation | Związki heterocykliczne jako immunomodulatory |
| EP3484866B1 (en) | 2016-07-14 | 2022-09-07 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| GB201614134D0 (en) * | 2016-08-18 | 2016-10-05 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| ES2941716T3 (es) | 2016-08-29 | 2023-05-25 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
| US20180179201A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| KR102696516B1 (ko) | 2016-12-22 | 2024-08-22 | 인사이트 코포레이션 | 면역조절제로서의 벤조옥사졸 유도체 |
| WO2018119286A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Bicyclic heteroaromatic compounds as immunomodulators |
| MY197501A (en) | 2016-12-22 | 2023-06-19 | Incyte Corp | Tetrahydro imidazo[4,5-c]pyridine derivatives as pd-l1 internalization inducers |
| EP3558973B1 (en) | 2016-12-22 | 2021-09-15 | Incyte Corporation | Pyridine derivatives as immunomodulators |
| EP4212529B1 (en) | 2018-03-30 | 2025-01-29 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| FI4219492T3 (fi) | 2018-05-11 | 2025-02-17 | Incyte Corp | Heterosyklisiä yhdisteitä immunomodulaattoreina |
| WO2020061103A1 (en) | 2018-09-18 | 2020-03-26 | Nikang Therapeutics, Inc. | Fused tricyclic ring derivatives as src homology-2 phosphatase inhibitors |
| EP3876939A4 (en) | 2018-11-07 | 2022-08-10 | Dana-Farber Cancer Institute, Inc. | Benzothiazole derivatives and 7-aza-benzothiazole derivatives as janus kinase 2 inhibitors and uses thereof |
| CA3150434A1 (en) | 2019-08-09 | 2021-02-18 | Incyte Corporation | Salts of a pd-1/pd-l1 inhibitor |
| AR120109A1 (es) | 2019-09-30 | 2022-02-02 | Incyte Corp | Compuestos de pirido[3,2-d]pirimidina como inmunomoduladores |
| IL292524A (en) | 2019-11-11 | 2022-06-01 | Incyte Corp | Salts and crystalline forms of a pd-1/pd-l1 inhibitor |
| EP4103188A4 (en) * | 2020-02-10 | 2024-04-10 | StemSynergy Therapeutics, Inc. | MYC INHIBITORS AND THEIR USES |
| BR112022022409A2 (pt) | 2020-05-06 | 2023-02-07 | Ajax Therapeutics Inc | 6-heteroarilóxi benzimidazóis e azabenzimidazóis como inibidores de jak2 |
| WO2022099075A1 (en) | 2020-11-06 | 2022-05-12 | Incyte Corporation | Crystalline form of a pd-1/pd-l1 inhibitor |
| PE20231438A1 (es) | 2020-11-06 | 2023-09-14 | Incyte Corp | Proceso para hacer un inhibidor de pd-1/pd-l1 y sales y formas cristalinas del mismo |
| US11780836B2 (en) | 2020-11-06 | 2023-10-10 | Incyte Corporation | Process of preparing a PD-1/PD-L1 inhibitor |
| EP4267574B1 (en) | 2020-12-23 | 2025-04-23 | Ajax Therapeutics, Inc. | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors |
| WO2023086320A1 (en) | 2021-11-09 | 2023-05-19 | Ajax Therapeutics, Inc. | Forms and compositions of inhibitors of jak2 |
| US11970494B2 (en) | 2021-11-09 | 2024-04-30 | Ajax Therapeutics, Inc. | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002049632A1 (en) * | 2000-12-18 | 2002-06-27 | Institute Of Medicinal Molecular Design. Inc. | Inhibitors against the production and release of inflammatory cytokines |
| WO2002051409A1 (en) * | 2000-12-22 | 2002-07-04 | Geron Corporation | Telomerase inhibitors and methods of their use |
| JP2009501778A (ja) * | 2005-07-20 | 2009-01-22 | アバンテイス・フアルマ・エス・アー | １，４−ジヒドロピリジン縮合ヘテロ環、これらの調製法、使用およびこれらを含有する組成物 |
| WO2011063602A1 (zh) * | 2009-11-27 | 2011-06-03 | 华东理工大学 | 5-取代-2，4-噻唑烷二酮类化合物在制备igf1r功能调节药物中的应用 |
| WO2012033149A1 (ja) * | 2010-09-10 | 2012-03-15 | 塩野義製薬株式会社 | Ａｍｐｋ活性化作用を有するヘテロ環縮合イミダゾール誘導体 |
| JP2012508260A (ja) * | 2008-11-10 | 2012-04-05 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ａｔｒキナーゼの阻害剤として有用な化合物 |
| JP2013512903A (ja) * | 2009-12-04 | 2013-04-18 | サイリーン ファーマシューティカルズ インコーポレーティッド | Ｃｋ２阻害剤としてのピラゾロピリミジンおよび関連複素環化合物 |
| WO2014159837A1 (en) * | 2013-03-14 | 2014-10-02 | Convergene Llc | Methods and compositions for inhibition of bromodomain-containing proteins |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH02191695A (ja) | 1989-01-20 | 1990-07-27 | Dainippon Ink & Chem Inc | 強誘電性液晶組成物 |
| JPH02194085A (ja) | 1989-01-24 | 1990-07-31 | Dainippon Ink & Chem Inc | 強誘電性液晶組成物 |
| JPH02196887A (ja) | 1989-01-26 | 1990-08-03 | Dainippon Ink & Chem Inc | 強誘電性液晶組成物 |
| JPH02208392A (ja) | 1989-02-08 | 1990-08-17 | Dainippon Ink & Chem Inc | 強誘電性液晶組成物 |
| JPH02222488A (ja) | 1989-02-23 | 1990-09-05 | Dainippon Ink & Chem Inc | 強誘電性液晶組成物 |
| JPH02227489A (ja) | 1989-02-28 | 1990-09-10 | Dainippon Ink & Chem Inc | 強誘電性液晶組成物 |
| JPH02227490A (ja) | 1989-02-28 | 1990-09-10 | Dainippon Ink & Chem Inc | 強誘電性液晶組成物 |
| JPH02227491A (ja) | 1989-03-01 | 1990-09-10 | Dainippon Ink & Chem Inc | 強誘電性液晶組成物 |
| JPH02242882A (ja) | 1989-03-16 | 1990-09-27 | Dainippon Ink & Chem Inc | 強誘電性液晶組成物 |
| JPH02247280A (ja) | 1989-03-20 | 1990-10-03 | Dainippon Ink & Chem Inc | 強誘電性液晶組成物 |
| JPH02247282A (ja) | 1989-03-22 | 1990-10-03 | Dainippon Ink & Chem Inc | 強誘電性液晶組成物 |
| JPH02255794A (ja) | 1989-03-29 | 1990-10-16 | Dainippon Ink & Chem Inc | 強誘電性液晶組成物 |
| JPH02255793A (ja) | 1989-03-30 | 1990-10-16 | Dainippon Ink & Chem Inc | 強誘電性液晶組成物 |
| US5965574A (en) | 1996-08-13 | 1999-10-12 | Chen; Yuhpyng Liang | Heteroaryl amines as novel acetylcholinesterase inhibitors |
| JPH08231541A (ja) | 1995-03-01 | 1996-09-10 | Nippon Soda Co Ltd | イミダゾリン誘導体および除草剤 |
| AU6331099A (en) * | 1998-09-30 | 2000-04-17 | Roche Diagnostics Gmbh | Thiazolidine derivatives for the treatment and prevention of metabolic bone disorders |
| JP2002527520A (ja) | 1998-10-21 | 2002-08-27 | ノボ ノルディスク アクティーゼルスカブ | 新規化合物、その製造及び使用 |
| JP2003057783A (ja) | 2001-08-21 | 2003-02-26 | Konica Corp | 銀色調を改良した光熱写真画像形成材料 |
| JP2003075955A (ja) | 2001-09-03 | 2003-03-12 | Konica Corp | 銀色調を改良した光熱写真画像形成材料 |
| JP2003075957A (ja) | 2001-09-07 | 2003-03-12 | Konica Corp | スケイル模様のない光熱写真画像形成材料 |
| HUP0401492A3 (en) * | 2001-09-14 | 2008-05-28 | Novo Nordisk As | Novel ligands for the hisb10 zn2+ sites of r-state insulin hexa |
| US20050042674A9 (en) * | 2002-02-21 | 2005-02-24 | Lin Yu | Common ligand mimics: thiazolidinediones and rhodanines |
| GB2387172A (en) * | 2002-03-28 | 2003-10-08 | Pantherix Ltd | [(Aryl-/arylthio-)aryl]methylene substituted azole & azine derivatives and their therapeutic use as antibacterials |
| US7348348B2 (en) * | 2002-04-30 | 2008-03-25 | Merck & Co. Inc. | Aryl-link-aryl substituted thiazolidine-dione and oxazolidine-dione as sodium channel blockers |
| JP4211433B2 (ja) | 2002-08-14 | 2009-01-21 | 三菱化学株式会社 | 有機金属錯体、発光色素、有機電界発光素子材料および有機電界発光素子 |
| WO2004080989A1 (ja) | 2003-03-10 | 2004-09-23 | Sumitomo Chemical Company Limited | フラン化合物の製造方法 |
| US7777051B2 (en) | 2003-05-13 | 2010-08-17 | Icagen, Inc. | Asymmetric benzimidazoles and related compounds as potassium channel modulators |
| ES2530972T3 (es) | 2003-09-12 | 2015-03-09 | Elixir Pharmaceuticals Inc | Métodos de tratamiento de trastornos |
| US20060074124A1 (en) | 2003-09-12 | 2006-04-06 | Andrew Napper | Methods of treating a disorder |
| US7842941B2 (en) | 2003-10-06 | 2010-11-30 | Sumitomo Chemical Company, Limited | Aromatic compound |
| WO2006005683A1 (en) * | 2004-07-09 | 2006-01-19 | Novo Nordisk A/S | Phamaceutical preparations comprising insulin |
| JP2006084592A (ja) | 2004-09-14 | 2006-03-30 | Fuji Photo Film Co Ltd | 感光性組成物 |
| US20090022694A1 (en) | 2005-10-18 | 2009-01-22 | Distefano Peter | Sirt1 inhibition |
| JP4931434B2 (ja) | 2006-02-14 | 2012-05-16 | 株式会社ダイセル | アミノ基含有アダマンタン誘導体とその製造方法 |
| WO2007146712A2 (en) | 2006-06-09 | 2007-12-21 | Kemia, Inc. | Therapy using cytokine inhibitors |
| EP2049548A1 (en) | 2006-07-27 | 2009-04-22 | UCB Pharma, S.A. | Fused oxazoles & thiazoles as histamine h3- receptor ligands |
| AU2008345225A1 (en) | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
| CA2710474A1 (en) | 2008-01-24 | 2009-07-30 | Ucb Pharma, S.A. | Compounds comprising a cyclobutoxy group |
| JP2011517317A (ja) | 2008-02-28 | 2011-06-02 | ライフ テクノロジーズ コーポレーション | 蛍光偏光ｈＥＲＧアッセイ法 |
| WO2010058402A1 (en) * | 2008-11-20 | 2010-05-27 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Novel anti-biofilm agents |
| US20120040916A1 (en) | 2008-12-22 | 2012-02-16 | Massachusetts Institute Of Technology | Molecular inhibitors of the wnt/beta-catenin pathway |
| JP5046213B2 (ja) | 2009-03-12 | 2012-10-10 | 独立行政法人科学技術振興機構 | 光学活性アルコール化合物の製法 |
| WO2012153780A1 (ja) | 2011-05-11 | 2012-11-15 | 出光興産株式会社 | 新規化合物、有機エレクトロルミネッセンス素子用材料及び有機エレクトロルミネッセンス素子 |
| WO2013038650A1 (ja) | 2011-09-13 | 2013-03-21 | 出光興産株式会社 | 縮合複素芳香族誘導体、有機エレクトロルミネッセンス素子用材料及びそれを用いた有機エレクトロルミネッセンス素子 |
| EP2887804B1 (en) | 2012-05-22 | 2021-01-27 | Trustees of Dartmouth College | Cycloalkanyl[b]indoles useful as glp-1 modulators |
| WO2014132971A1 (ja) | 2013-02-28 | 2014-09-04 | 住友化学株式会社 | 縮合複素環化合物及びその有害生物防除用途 |
| US9242944B2 (en) | 2013-03-27 | 2016-01-26 | University Of Maryland, Baltimore | Potent analogues of the C-Myc inhibitor 10074-G5 with improved cell permeability |
| CN106456616A (zh) | 2013-12-11 | 2017-02-22 | 斯克利普斯研究院 | 小分子C‑Myc抑制剂 |
-
2015
- 2015-12-10 JP JP2017531478A patent/JP2017537940A/ja active Pending
- 2015-12-10 EP EP15820938.7A patent/EP3230279A1/en not_active Withdrawn
- 2015-12-10 US US14/965,549 patent/US10017520B2/en active Active
- 2015-12-10 WO PCT/US2015/065044 patent/WO2016094688A1/en not_active Ceased
- 2015-12-10 AU AU2015360416A patent/AU2015360416A1/en not_active Abandoned
- 2015-12-10 CA CA2968884A patent/CA2968884A1/en not_active Abandoned
-
2018
- 2018-06-11 US US16/005,455 patent/US20200048276A9/en not_active Abandoned
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002049632A1 (en) * | 2000-12-18 | 2002-06-27 | Institute Of Medicinal Molecular Design. Inc. | Inhibitors against the production and release of inflammatory cytokines |
| WO2002051409A1 (en) * | 2000-12-22 | 2002-07-04 | Geron Corporation | Telomerase inhibitors and methods of their use |
| JP2009501778A (ja) * | 2005-07-20 | 2009-01-22 | アバンテイス・フアルマ・エス・アー | １，４−ジヒドロピリジン縮合ヘテロ環、これらの調製法、使用およびこれらを含有する組成物 |
| JP2012508260A (ja) * | 2008-11-10 | 2012-04-05 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ａｔｒキナーゼの阻害剤として有用な化合物 |
| WO2011063602A1 (zh) * | 2009-11-27 | 2011-06-03 | 华东理工大学 | 5-取代-2，4-噻唑烷二酮类化合物在制备igf1r功能调节药物中的应用 |
| JP2013512903A (ja) * | 2009-12-04 | 2013-04-18 | サイリーン ファーマシューティカルズ インコーポレーティッド | Ｃｋ２阻害剤としてのピラゾロピリミジンおよび関連複素環化合物 |
| WO2012033149A1 (ja) * | 2010-09-10 | 2012-03-15 | 塩野義製薬株式会社 | Ａｍｐｋ活性化作用を有するヘテロ環縮合イミダゾール誘導体 |
| WO2014159837A1 (en) * | 2013-03-14 | 2014-10-02 | Convergene Llc | Methods and compositions for inhibition of bromodomain-containing proteins |
Non-Patent Citations (21)
| Title |
|---|
| JOURNAL OF MEDICINAL CHEMISTRY, vol. 57, JPN6019036133, 2014, pages 5693 - 5701, ISSN: 0004268792 * |
| NATURE CHEMICAL BIOLOGY, vol. 1(3), JPN6019036150, 2005, pages 167 - 173, ISSN: 0004268805 * |
| PLOS ONE, vol. 8(4), JPN6019036148, 2013, pages 1 - 9, ISSN: 0004268804 * |
| REGISTRY(STN), JPN7019003003, 2001, ISSN: 0004268793 * |
| REGISTRY(STN), JPN7019003006, 2004, ISSN: 0004268794 * |
| REGISTRY(STN), JPN7019003007, 2002, ISSN: 0004268795 * |
| REGISTRY(STN), JPN7019003008, 2002, ISSN: 0004268796 * |
| REGISTRY(STN), JPN7019003009, 2003, ISSN: 0004268798 * |
| REGISTRY(STN), JPN7019003010, 2002, ISSN: 0004268799 * |
| REGISTRY(STN), JPN7019003011, 2002, ISSN: 0004268800 * |
| REGISTRY(STN), JPN7019003012, 2002, ISSN: 0004268801 * |
| REGISTRY(STN), JPN7019003013, 2001, ISSN: 0004268802 * |
| REGISTRY(STN), JPN7019003014, 2013, ISSN: 0004268806 * |
| REGISTRY(STN), JPN7019003015, 2004, ISSN: 0004268808 * |
| REGISTRY(STN), JPN7019003016, 2013, ISSN: 0004268809 * |
| REGISTRY(STN), JPN7019003017, 2013, ISSN: 0004268810 * |
| REGISTRY(STN), JPN7019003018, 2011, ISSN: 0004268811 * |
| REGISTRY(STN), JPN7019003019, 2002, ISSN: 0004268812 * |
| REGISTRY(STN), JPN7019003020, 2004, ISSN: 0004268797 * |
| SYNTHETIC COMMUNICATIONS, vol. 43(14), JPN6019036147, 2013, pages 1882 - 1895, ISSN: 0004268803 * |
| TETRAHEDRON LETTERS, vol. 52, JPN6019036155, 2011, pages 3347 - 3352, ISSN: 0004268807 * |
Also Published As
| Publication number | Publication date |
|---|---|
| US10017520B2 (en) | 2018-07-10 |
| CA2968884A1 (en) | 2016-06-16 |
| US20160168165A1 (en) | 2016-06-16 |
| EP3230279A1 (en) | 2017-10-18 |
| WO2016094688A1 (en) | 2016-06-16 |
| US20200048276A9 (en) | 2020-02-13 |
| US20180291035A1 (en) | 2018-10-11 |
| AU2015360416A1 (en) | 2017-06-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017537940A (ja) | 増殖性疾患の処置に有用な融合１，３−アゾール誘導体 | |
| US11932625B2 (en) | Inhibitors of cyclin-dependent kinase 12 (CDK12) and uses thereof | |
| JP6854762B2 (ja) | サイクリン依存性キナーゼ７（ｃｄｋ７）の阻害剤 | |
| JP7308146B2 (ja) | インターロイキン１受容体関連キナーゼの阻害剤およびその使用 | |
| JP6861166B2 (ja) | サイクリン依存性キナーゼの阻害剤 | |
| CN113993519B (zh) | 细胞周期蛋白依赖性激酶12(cdk12)的降解剂及其用途 | |
| US12415816B2 (en) | Benzothiazole derivatives and 7-aza-benzothiazole derivatives as janus kinase 2 inhibitors and uses thereof | |
| JP2017512186A (ja) | ジヒドロプテリジノン誘導体およびその使用 | |
| JP6788583B2 (ja) | 増殖性疾患を処置するためのチアゾリル含有化合物 | |
| JP2018522867A (ja) | 縮合二環式ピリミジン誘導体およびこれらの使用 | |
| US10865213B2 (en) | Max binders as MYC modulators and uses thereof | |
| JP2020529998A (ja) | 血漿カリクレインの阻害剤およびその使用 | |
| JP2021514955A (ja) | プロテアソーム関連ユビキチン受容体ｒｐｎ１３機能を阻止する低分子およびその使用法 | |
| JP2021529174A (ja) | Ｄｏｔ１ｌディグレーダーおよびその使用 | |
| JP7185631B2 (ja) | 抗線維化化合物 | |
| US20230382865A1 (en) | Histone demethylase 5 inhibitors and uses thereof | |
| US20230339865A1 (en) | Quinazoline-derived hck inhibitors for use in the treatment of myd88 mutated diseases | |
| WO2017151625A1 (en) | 4,9-dioxo-4,9-dihydronaphtho(2,3-b)furan-3-carboxmide derivatives and uses thereof for treating proliferative diseases and infectious diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20181210 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20181210 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20181219 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20190912 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190919 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20191213 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20200526 |